AGER and prostate cancer: The results showed that the intersecting targets were primarily enriched in pathways related to caffeine metabolism, bladder cancer, the role of the advanced glycation end products-receptor for advanced glycation end products (AGE-RAGE) signaling pathway in diabetic complications, non-small cell lung cancer, prostate cancer, epidermal growth factor receptor tyrosine kinase inhibitor resistance, pancreatic cancer, vascular endothelial growth factor (VEGF) signaling pathway, glioma, chronic myeloid leukemia, and acute myeloid leukemia.